← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Varex Imaging Corp: Revenue grew 4.1% to $845M from $811M. Net loss widened to $70.3M from $48.8M. Free cash flow declined 7.8% to $18.8M from $20.4M. Operating margin contracted 725 bps to -3.29%. Varex Imaging Corp's annual comparison also shows free cash flow declined despite revenue growth; margins improved while free cash flow declined; inventory grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 4.1% to $845M from $811MOK
- Profitability — Net loss widened to $70.3M from $48.8MWatch
- Cash flow — Free cash flow declined 7.8% to $18.8M from $20.4MWatch
- Margins — Operating margin contracted 725 bps to -3.29%Watch
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 3 salesWatch
Business
Product and Other Liabilities Our business exposes us to potential product liability claims that are inherent in the manufacture, sale, installation, servicing and support of X-ray imaging devices, related software and other devices that contain hazardous material or deliver radiation.
Where the revenue comes from
Fiscal 2025, as Varex Imaging Corp reports it. History and quarterly detail are in the app.
- Medical$592.6M
- Industrial$252.0M
Latest filings
- 8-K · Company announcement2026-08-10
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-08-10
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Varex Imaging Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.